Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review-Reference-Cited by-同舟云学术

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

Published:2018-06 Issue: Volume:140 Page:118-128
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Rådholm Karin,Wu Jason HY,Wong Muh Geot,Foote Celine,Fulcher Gregory,Mahaffey Kenneth W.,Perkovic Vlado,Neal Bruce

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference56 articles.

1. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysis;Vasilakou;Ann Intern Med,2013

2. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis;Wu;Lancet Diabetes Endocrinol,2016

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

4. Bone disturbances in injury to spinal cord and cauda equina (paraplegia): their prevention by ambulation;Abramson;J Bone Joint Surg,1948

5. U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood: Food and Drug Administration; 2015 https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

2. Assessing the use of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and chronic kidney disease in tertiary care: a SwissDiab Study;BMJ Open Diabetes Research & Care;2024-06

3. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10

4. Therapie des Typ-2-Diabetes;Die Diabetologie;2024-01-30

5. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System;Expert Opinion on Drug Safety;2023-11-27